title: [Severe acute cytomegalovirus colitis after administration of irinotecan and raltitrexed chemotherapy].
authors.forename: Jérôme
authors.initials: J
authors.lastname: Dumortier
authors.forename: José
authors.initials: J
authors.lastname: Villarejo
authors.forename: Marie-George
authors.initials: MG
authors.lastname: Lapalus
authors.forename: Véronique
authors.initials: V
authors.lastname: Vochelle
authors.forename: Olivier
authors.initials: O
authors.lastname: Beatrix
authors.forename: Jean-Yves
authors.initials: JY
authors.lastname: Scoazec
authors.forename: Catherine
authors.initials: C
authors.lastname: Lombard-Bohas
mesh_terms: D000208:Acute Disease; D000230:Adenocarcinoma / Q000188:drug therapy; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects*; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D000998:Antiviral Agents / Q000627:therapeutic use; D002166:Camptothecin / Q000009:adverse effects* / Q000031:analogs & derivatives*; D003092:Colitis / Q000139:chemically induced* / Q000188:drug therapy / Q000276:immunology; D003586:Cytomegalovirus Infections / Q000139:chemically induced* / Q000188:drug therapy / Q000276:immunology; D015774:Ganciclovir / Q000627:therapeutic use; D006801:Humans; D016867:Immunocompromised Host; D000077146:Irinotecan; D008297:Male; D011799:Quinazolines / Q000009:adverse effects*; D012004:Rectal Neoplasms / Q000188:drug therapy; D012811:Sigmoid Neoplasms / Q000188:drug therapy; D013876:Thiophenes / Q000009:adverse effects*
chemical_list: D000964:Antimetabolites, Antineoplastic; D000972:Antineoplastic Agents, Phytogenic; D000998:Antiviral Agents; D011799:Quinazolines; D013876:Thiophenes; D000077146:Irinotecan; C068874:raltitrexed; D015774:Ganciclovir; D002166:Camptothecin
vernacular_title: Colite aiguë grave à cytomegalovirus après chimiothérapie par irinotécan et raltitrexed.